Clinical Trial

Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia

Study acronym: BRZ-WM
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Current retrospective studies have demonstrated that achieving deep remission following treatment for Waldenström's macroglobulinemia (WM) correlates with prolonged survival. While the bendamustine-rituximab (BR) regimen or single-agent zanubrutinib are currently recommended as first-line therapies, neither achieves optimal deep remission. Additionally, prolonged zanubrutinib monotherapy may lead to cumulative adverse effects. Therefore, this study aims to evaluate the efficacy and safety of the bendamustine-rituximab-zanubrutinib combination regimen as a first-line treatment option for MYD88-mutated WM patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-17.
Trial Details
NCT Number NCT06942507
Lead Sponsor Peking Union Medical College Hospital
Conditions Waldenström's Macroglobulinemia (WM)
Enrollment 104 participants
Start Date 2025-05-01
Primary Completion 2027-04-30 (estimated)
Study Completion 2029-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-30